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Auto Transplants for Minireview
Parkinson's Disease?
possibly because the number of endogenous dopami-
nergic neurons that can utilize it becomes too low.




South San Francisco, California 94080 in the globus pallidus (pallidotomy) have been tried. Pal-
lidotomy was practiced prior to the development of
The Disease L-DOPA, discarded, and recently regained acceptance
Parkinson's disease is the third most common neurode- (Lang et al., 1997). The rationale behind pallidotomy is
generative disorder, with a prevalence of approximately easy to understand. Since in the absence of dopaminer-
1% of the population over 65. Affected individuals suffer gic inputs the globus pallidus is hyperactive, selective
from debilitating deficiencies in motor functions that lesions will weaken its activity and reduce it to normal
manifest in (1) rhythmic tremors at rest, (2) inability to levels. Similar rationale also led to the usage of high-
initiate (akinesia) or complete (bradykinesia) routine frequency (inhibitory) electrical stimulation in the sub-
movements, (3) muscle rigidity that leads to jerked mo- thalamic nucleus. The subthalamic nucleus normally
tions, (4) postural instability, and (5) lack of facial expres- stimulates the globus pallidus, and its inhibition helps
sion. The disease is predominantly nonfamilial and does reduce globus pallidus activity (Figure 1).
not show gender or racial bias. It is invariably progres- Although pallidotomy and electrical stimulation show
sive and 5±10 years after onset the worst patients are promise in reducing akinesia and bradykinesiaÐespe-
left bedridden and dieof infections or secondary compli- cially akinesia that is induced by L-DOPA in advanced
cations. Parkinson's patientsÐthey are not consistently effec-
The clinical symptoms are caused by a selective loss tive in reducing tremors. In addition, many symptoms
of pigmented dopamine-producing neurons from the recur after only a few years. Thus, a third therapeutic
substantia nigra in the midbrain and a consequent de-
approach was called forÐtransplantation (Yurek and
crease in dopamine at the innervation targets of these
Sladek, 1990). The rationale behind transplantation for
neurons, which include the striatum, cortex, and nucleus
Parkinson's disease is again straightforward: the ideaaccumbens.
is to replace lost dopaminergic neurons with a graft ofThe cause of cell death in Parkinson's disease is un-
new embryonic neurons. Transplantation of fetal dopa-known. Viral infections, environmental toxins, and oxida-
minergic neurons into rodent models of Parkinson's dis-tive stress induced by dopamine metabolites, are all
ease was pioneered in the early 1980s (BjoÈ rklund andsuspected. In contrast, the consequence of dopaminer-
Stenevi, 1979; Perlow et al., 1979). In these initial experi-gic neuron loss for the neural circuits that control move-
ments, approximately 150,000 ventral midbrain neuralment is well understood. The dopaminergic neurons are
progenitors were transplanted, of which 10,000 werean integral part of the basal ganglia, a group of forebrain
nuclei that play an important role in motor control. In
their absence, excessive inhibitory stimuli are sent from
the basal ganglia through the globus pallidus to the
thalamus, leading to a decrease in motor cortex activity
and to the negative symptoms of Parkinson's disease:
akinesia, bradykinesia, and rigidity. In addition, the loss
of a feedback loop between the nigral dopaminergic
neurons and the thalamus leadsto the release of sponta-
neous periodic impulses in the thalamus, which are re-
sponsible in part for the characteristic tremors (Figure
1) (CoÃ teÂ and Crutcher, 1991).
What Can Be Done?
Over the years, several therapeutic approaches have
been developed to counteract or compensate for the
neural or chemical deficiencies that underlie Parkinson's
disease (Table 1, Figure 1). The most prevalent among
these is intravenous injection of L-DOPA, which was
pioneered in the 1950s. L-DOPA is a precursor for dopa-
mine; it crosses the blood±brain barrier and is most
likely taken up by the remaining dopaminergic neurons
and nerve terminals, where it is converted to dopamine.
L-DOPA compensates for the reduction in the level of
endogenous dopamine, increases the levels of dopa-
mine in the striatum, and leads to a reversal or ameliora-
tion of akinesia, bradykinesia, and rigidity (Birkmayer
and Hornykiewicz, 1976). Unfortunately, it is not effective Figure 1. Neuronal Circuits in Normal and Parkinson's Brain
in reducing tremors, nor does it slow the disease pro- A simplified and partial description of neural connections affected
gression. After several years of treatment, L-DOPA pro- by midbrain dopaminergic neurons in normal and Parkinson's brain
and of the therapeutic approaches (after CoÃ teÂ and Crutcher, 1991).duces severe side effects and is no longer efficacious,
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Table 1. Therapeutic Approaches to Parkinson's Disease
Therapeutic Approach Rationale Limitation
L-DOPA enhance dopamine production not effective in late stages PD; does
not prevent disease progression;
does not prevent tremors
Pallidotomy/partial surgical lesion decrease the excessive no consistent reversal of
in globus pallidus inhibitory effect of globus tremors; akinesia and bradykinesia
pallidus on the thalamus may reoccur
Survival factors prevent degeneration of difficult to deliver not
DA neurons tried in human
Transplantation of replace missing DA neurons no adequate cell source
DA-producing cells
dopaminergic neurons. Unfortunately, due to the low Xenografts of porcine dopaminergic neurons were also
successfully grafted in animal models, but the risk ofoxygen tension or to the absence of appropriate survival
factors, only 1%±10% of the grafted cells (100±1000 interspecies viral infection may prohibit their usage in
the clinic (Galpern et al., 1996). Finally, attempts aredopaminergic neurons) survived more than a few days.
Compared to the substantia nigra of a normal rat, which being made to recapitulate the ontogeny of dopaminer-
gic neurons (Hynes et al., 1995) and to produce themcontains z30,000 dopaminergic neurons, the number
of stably grafted neurons was quite low. Nevertheless, in large amounts in a test tube. However, these studies
are in the early experimental phases. Now, in this issueit was sufficient to restore some of the motor deficits in
the rodent Parkinsonian model and to justify clinical of Neuron, Dr. LoÂ pez-Barneo and colleagues (Espejo et
al., 1998) describe another source of cells for trans-trials in human.
Human clinical trials using dopaminergic neurons plantation, the glomus cells of the carotid bodies.
The carotid bodies in human are 5 mm long nodulesfrom aborted human fetuses were conducted in the late
1980s (Lindvall et al., 1988; Madrazo et al., 1988). These located near the carotid sinus. They are estimated to
be composed of at least 100,000 epithelial ªglomusºtrials revealed a dramatic improvement in motor func-
tion, a decreased dependence on L-DOPA, and an in- (type I) cells and 4,000±8,000 support or sheath (type
II) cells (J. LoÂ pez-Barneo, personal communication),crease in the levels of striatal dopamine in some pa-
tients. Other patients, however, showed no benefits and and their function is to monitor changes in blood lev-
els of O2, CO2, and H1 brought about by physiologicalcontinued to decline. As in the animal models, the vari-
ability among human transplant recipients was subse- stressors such as hypoxia, high altitude, and exercise.
Changes in blood gases, detected by the carotid bodies,quently shown to result from the poor survival rate of
the transplanted cells. The amount of dopamine pro- are then reported to the medulla through the carotid
sinus nerve, a component of the IX cranial nerve, andduced by the few surviving neurons was often not suffi-
cient to ameliorate the motor deficits. As a consequence lead to an alteration in breathing that allows adequate
gas exchange to meet the body's metabolic demandsof these findings the number of transplanted cells was
significantly increased. Today, up to 500,000 midbrain (Berger and Hornbein, 1989). Interestingly, the glomus
cells, whose embryonic origin is the neural crest, haveprecursors, containing z30,000 dopaminergic neurons
(equivalent to the number of dopaminergic neurons in some neuronal-like characters and are rich in dopamine.
Whereas neurons will degenerate and die at the lowthe entire rat substantia nigra) are being used in the
rodent Parkinson's model (with the aid of antioxidants, oxygen tensions characteristic of the transplant environ-
ment, glomus cells thrive in hypoxic conditions, produc-the percentage of surviving cells has been increased
to 20% or 6000 dopaminergic neurons; A. BjoÈ rklund, ing and secreting even greater amounts of dopamine.
To test the efficacy of glomus cell grafts in a model ofpersonal communication). Likewise, it is now accept-
able to use cells from up to 10 human fetuses for a Parkinson's disease, LoÂpez-Barneo's group transplanted
them into one side of the rat substantia nigra, whichsingle graft into a Parkinson's patient. Although this
increase in cell number has led to a more consistent had been destroyed by injection of the neurotoxin
6-Hydroxydopamine (Schwarting and Huston, 1996).and favorable clinical outcome, it nonetheless renders
this type of transplantation therapy impractical as a rou- Prior to transplantation, these rats had a reduction of
.90% in the number of dopaminergic neurons in thetine treatment.
The Carotid Body lesioned side, and a similar decrease in the amount of
dopamine in the ipsilateral striatum. These rats exhibitedGiven the potential benefit of transplantation, alternative
sources of cells that can provide dopamine are con- significant abnormalities in motor function including: (1)
spontaneous rotation toward the lesioned side that wasstantly being explored (Figure 1, Table 2). For example,
adrenal medulla cells were tested in animal models and accentuated following treatment with amphetamine
(amphetamine promotes flux reversal by plasma mem-in humans (Yurek and Sladek, 1990). However, only
1/1000 of these cells survived the striatal environment brane monamine transporters, thereby releasing dopa-
mine); (2) a 50% decrease in free locomotion that mayfor more than a few days. Moreover, although adrenal
medulla cells make dopamine, they do not secrete it reflect an inability to initiate movement (akinesia); (3) an
increased response time in the whisker touch test, aefficiently and therefore their therapeutic benefit is poor.
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Table 2. Sources of Transplanted Cells
Potential Sources Advantage Limitations
Human fetal DA neurons innervate the striatum; showed efficacy no adequate source; low survival rate;
possible immune response
Human fetal DA generated in vitro abundant source not achieved yet
Porcine DA neurons abundant source intraspecies viral infections; possible
immune response
Dopamine-producing fibroblasts abundant source no innervation; no regulated secretion
of dopamine
Adrenal medullary cells abundant source no long-term survival; no dopamine
secretion
Carotid body autotransplants no immune response; survive well in small number of cells; efficacy in
hypoxic condition; good innervation; reversing akinesia not demonstrated
may produce survival factors; induce
rapid recovery in an animal model
measure of sensorimotor orientation; and (4) asymmetry finding that 400 glomus cells could improve sensorimo-
tor tests may again indicate that they make and secretein the direction of movement along the cage wall, a
measure of sensorimotor neglect. more dopamine than dopaminergic neurons and are
therefore more efficient in rescuing motor deficits. Alter-Of the 400±600 glomus cells that were grafted (rats
have 2,000±3,000 glomus cells per carotid body), over natively, differences in the experimental paradigms may
be responsible for the apparent discrepancies. Side-by-60% survived for the entire duration of the experiments,
which is a significantly better survival rate than for adre- side comparison of these two cell types will have to be
conducted to resolve this issue.nal medulla cells or fetal dopaminergic neurons. More-
over, three months following the transplantation, some Lesioned animals that received the glomus cell grafts
did not improve in the test of distance traveled in anof the glomus cells extended through the host tissue
fibers with varicose presynaptic-like structures, allowing open field, indicating that their ability to initiate and
execute movements is still impaired. Reversal of thisregulated and widespread release of dopamine.
The second piece of good news is that the lesioned symptom, however, may require transplantation into
the nucleus accumbens, a distinct innervation target ofanimals showed a rapid recovery from biochemical and
motor deficits. Dopamine levels in the transplanted side dopaminergic neurons, which lies outside of the basal
ganglia. LoÂ pez-Barneo and colleagues did not yet at-increased from 11% to 65%of thecontralateral striatum;
the animals no longer exhibited significant spontaneous, tempt this.
An additional benefit of the carotid body grafts liesor amphetamine-induced rotation; and their scores im-
proved in two of the three sensorimotor tests. in their potential ability to induce arborization of the
endogenous dopaminergic terminals. Such sprouting ofThe significant increase in striatal dopamine following
transplantation of only 400±600 glomus cells is surpris- the resident dopaminergic neurons, which is not ob-
served with transplants of fetal neurons, may suggesting given the fact that the rat striatum is normally inner-
vated by z30,000 dopaminergic neurons. This finding that the carotid cells secrete, in addition to dopamine,
a survival or a sprouting factor for dopaminergic neu-may suggest that glomus cells produce a lot more dopa-
mine than the endogenous dopaminergic neurons (com- rons. A survival factor could greatly enhance the thera-
peutic potential of carotid body cells since it may beparison of reported dopamine contents in glomus cells
and dopaminergic neurons from different species indeed able to protect endogenous dopaminergic neurons from
further degeneration. In fact, part of the observed im-suggest that glomus cellsmay contain 3- to45-fold more
dopamine; J. LoÂ pez-Barneo, personal communication). provement in the sensorimotor test could be attributed
to sprouting of the endogenous dopaminergic neurons.Alternatively, since the neurons responsible for dopa-
mine re-uptake have been lesioned, the high levels of Although the carotid bodies are necessary for ade-
quate ventilation in response to low oxygen, removaldopamine may reflect its accumulation in the extracellu-
lar environment rather than an elevated production ca- of one carotid body is not detrimental. Thus, another
advantage of the carotid bodies is that they could inpacity of the glomus cells. Additional measurements of
dopamine content in glomus cells and dopaminergic principle be used for autotransplantation, providing a
ready source of cells and eliminating the need for im-neurons in a single species will have to be performed
in order to distinguish between these two possibilities. mune suppression, which is now used as a precaution-
ary measure with the fetal grafts.The improvement in two sensorimotor tests is also
quite unexpected given the low number of transplanted The success of carotid body transplants in an animal
model for Parkinson's disease obviously points to theircells. Previous studies with fetal dopaminergic neurons
have suggested that 400 neurons can elicit recovery in potential use for auto transplants in humans. However,
before this is attempted, several fundamental issuesamphetamine-induced rotation but not in spontaneous
sensorimotor tests. In these experiments, measurable need to be addressed. Most important is the issue of cell
number. The limited experience with fetal dopaminergicrecovery in sensorimotor tests was achieved only in
the presence of 1,000±2,000 transplanted neurons. The transplants into human suggests that successful grafts
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Schwarting, R.K.W., and Huston, J.P. (1996). Prog. Neurobiol. 50,may have to contain z100,000±150,000 neurons (healthy
275±331.human substantia nigra contains z1,000,000 dopami-
Yurek, D.M., and Sladek, J.R. (1990). Annu. Rev. Neurosci. 13,nergic neurons). Would 60,000±100,000 glomus cells be
415±440.able to do the same job? Second, beneficial effect on
the more debilitating and difficult-to-reverse symptoms
of Parkinson's disease, akinesia and postural balance,
will have to be demonstrated. Finally, more information
on the ability of glomus cells to secrete neurotrophic
factors, and on the possible beneficial effects of the
neuropeptides (e.g., enkephalins, VIP) and neurotrans-
mitters (e.g., acetylcholine) that these cells produce, will
have to be gathered.
Even if a single carotid body is not a sufficient cell
source, the relative ease of purifying glomus cells and
their abundance in thecarotid body may allow thegener-
ation of useful glomus cell lines for grafting purposes.
In addition, studies on the mechanisms that support the
survival of glomus cells in the striatum may eventually
help in improving the survival rate of transplanted pri-
mary dopaminergic neurons.
Carotid body transplants have been tried before but
with less success (Bing et al., 1988). The difference ap-
pears to lie in the way thegrafts wereprepared in the two
studies. Whereas previous investigators use dispersed
cells, LoÂpez-Barneo and his colleagues used cell aggre-
gates, which probably allow better recovery and the
retention of the glomus cell phenotype.
For lack of an adequate cell source, transplantation
has not been a widely adopted therapeutic approach.
Although it is not the ideal therapy for Parkinson's dis-
ease, it does provide significant benefits. The glomus
cell grafts, which appear to provide an enriched source
of dopamine-producing cells that survive well, may
change this situation.
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